This article, from RGA's ReFlections, highlights how AI is opening new possibilities in cardiovascular health, with emerging tools helping clinicians identify potential heart disease earlier and more efficiently. A groundbreaking innovation offers potential implications for healthcare, risk assessment, and the future of preventive medicine.
In June 2026, the Food and Drug Administration (FDA) approved the world’s first AI tool to detect multiple structural heart diseases from a standard 12-lead electrocardiogram (ECG).
The technology, called EchoNext, received clearance for six cardiovascular indications and is designed to screen and identify patients at risk of serious heart conditions that may not be detectable through routine clinical interpretation of ECGs. Identified patients would then undergo an echocardiogram to confirm diagnosis.
EchoNext can flag conditions including left- and right-sided heart failure, valvular heart disease, pulmonary hypertension, and severe hypertrophy associated with infiltrative cardiomyopathies. The AI model was developed using more than 700,000 paired ECG-echocardiogram records and reportedly demonstrated higher diagnostic accuracy than cardiologists, including those using AI assistance. Its performance was shown to be robust through validation studies that involved over 500,000 patients across more than 20 hospitals in the U.S. and Canada. The company cited a case published in Nature Medicine1 where EchoNext identified previously undiagnosed heart failure that ultimately led to the first heart transplant resulting from AI-enabled disease detection.
The company also announced a partnership with OpenEvidence,2 a clinical AI platform reportedly used by more than half the physicians in the U.S., enabling wide-scale distribution of the tool at the point of care.
For healthcare payers, earlier detection of cardiovascular disease may increase short-term healthcare utilization through additional diagnostic testing, specialist consultations, and treatment, while potentially supporting improved long-term health outcomes and reducing the burden of advanced cardiac disease.
Widespread adoption may increase detection rates of previously undiagnosed cardiovascular disease and provide new insights into disease prevalence, with the potential to inform future risk assessment and portfolio management considerations.
RGA experts are eager to engage with clients to better understand and tackle the industry’s most pressing challenges together. Contact us to learn more about RGA's capabilities, resources, and solutions.
